True North Therapeutics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
17
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$825M
True North Therapeutics General Information
Description
Developer of innovative antibody therapeutics targeting the classical pathway of the complement system. The company's monoclonal antibody to treat cold agglutinin disease TNT009, selectively targets the classical pathway of the complement system and prevents the generation of critical inflammatory mediators and phagocytic markers not addressed by other therapeutic approaches that act by inhibiting the complement system further downstream.
Contact Information
Website
www.truenorthrx.comCorporate Office
- 951 Gateway Boulevard
- South San Francisco, CA 94080
- United States
Corporate Office
- 951 Gateway Boulevard
- South San Francisco, CA 94080
- United States
True North Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 28-Jun-2017 | $825M | Completed | Clinical Trials - Phase 1 | ||
| 6. Later Stage VC (Series D) | 18-Oct-2016 | Completed | Clinical Trials - Phase 1 | |||
| 5. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 4. Later Stage VC (Series C) | 03-Dec-2015 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series B) | 07-Apr-2015 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 17-Jun-2014 | $22M | $22M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
True North Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 29,166,580 | $0.000100 | $0.1 | $1.2 | $1.2 | 1x | $1.2 | 21.6% |
| Series A | 23,856,206 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 17.67% |
True North Therapeutics Comparisons
Industry
Financing
Details
True North Therapeutics Competitors (63)
One of True North Therapeutics’s 63 competitors is BioMarin Pharmaceutical, a Formerly PE-Backed company based in San Rafael, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA | ||||
| Protalix Biotherapeutics | Formerly VC-backed | Karmiel, Israel | ||||
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Renova Therapeutics | Venture Capital-Backed | Carlsbad, CA | ||||
| Cell Signaling Technology | Corporation | Danvers, MA |
True North Therapeutics Signals
True North Therapeutics Former Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ATEL Capital Group | Asset Manager | Minority | ||
| Baxalta | Corporation | Minority | ||
| Baxter Ventures | Corporate Venture Capital | Minority | ||
| Biogen | Corporation | Minority | ||
| Cowen Healthcare Investments | Venture Capital | Minority |
True North Therapeutics FAQs
-
When was True North Therapeutics founded?
True North Therapeutics was founded in 2013.
-
Where is True North Therapeutics headquartered?
True North Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of True North Therapeutics?
True North Therapeutics has 17 total employees.
-
What industry is True North Therapeutics in?
True North Therapeutics’s primary industry is Drug Discovery.
-
Is True North Therapeutics a private or public company?
True North Therapeutics is a Private company.
-
What is the current valuation of True North Therapeutics?
The current valuation of True North Therapeutics is .
-
What is True North Therapeutics’s current revenue?
The current revenue for True North Therapeutics is .
-
How much funding has True North Therapeutics raised over time?
True North Therapeutics has raised $142M.
-
Who are True North Therapeutics’s investors?
ATEL Capital Group, Baxalta, Baxter Ventures, Biogen, and Cowen Healthcare Investments are 5 of 18 investors who have invested in True North Therapeutics.
-
Who are True North Therapeutics’s competitors?
BioMarin Pharmaceutical, Protalix Biotherapeutics, Dicerna Pharmaceuticals, Renova Therapeutics, and Cell Signaling Technology are some of the 63 competitors of True North Therapeutics.
-
When was True North Therapeutics acquired?
True North Therapeutics was acquired on 28-Jun-2017.
-
Who acquired True North Therapeutics?
True North Therapeutics was acquired by Bioverativ Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process